Back
TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)
Poster Presentation

TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)

American Society of Clinical Psychopharmacology (ASCP), May 2024.
View Presentation

Summary of poster presentation:

  • Participants treated with TSND-201 had a positive impact on sleep.
  • TSND-201 showed improvements on the sleep-specific items of the Clinician Administered PTSD Scale for PTSD (CAPS-5), in addition to the total severity score.
  • Similarly, improvements on the sleep item of the Montgomery-Asberg Depression Rating Scale (MADRS) were improved after treatment with TSND-201.
  • Improvements in sleep were also consistently improved on the Pittsburgh Sleep Quality Index (PSQI), a general measure of overall sleep.

View Poster